A phase 3, randomised,active-controlled ,double-blind trial evaluating the safety, tolerability, and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine

Trial Profile

A phase 3, randomised,active-controlled ,double-blind trial evaluating the safety, tolerability, and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2012

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Aug 2012 Actual initiation date changed from 1 May 2007 to 1 Jun 2007 as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Study results have been reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA).
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed, according to a Wyeth media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top